You are now leaving myCME and connecting to our educational partner. myCME does not control content, practices, or other policies of the site you are entering.
1.00 / AMA PRA Category 1 Credit(s)TM
Despite clear evidence regarding the importance of a tumor’s molecular signature in treatment algorithms, too few clinicians routinely obtain such information. This webcast educates clinicians regarding the biochemical pathways that lead to trastuzumab resistance in HER2-positive tumors and current options to overcome such resistance or other options to increase progression-free survival.
Community oncologists, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and other health care professionals involved in the care and treatment of women with breast cancer.
At the end of this online enduring material, participants should be able to:
Beverly Moy, MD
Consulting: GlaxoSmithKline, Pfizer
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Society for Translational Oncology (STO) and Massachusetts General Hospital. The Society for Translational Oncology (STO) is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Society for Translational Oncology designates this enduring material for a maximum of one (1) AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Method of Participation:
To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.
If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.